

1 **Epidemiology and antibiotic resistance profile of *Helicobacter pylori***
2 **infection in Cameroon: a systematic review with meta-analysis**

3

First name	Last name	Email	Affiliations
Corinne Raïssa	Ngnamko	corinnengnameko@yahoo.fr	Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon
Jean Jacques	Noubiap	noubiapjj@yahoo.fr	Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia
Freddy Brice	Simo Nemg	nemgsi@yahoo.fr	Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon
Mohamadou Abdou	Galdima	mohamagaldima@yahoo.fr	Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Ngaoundéré, Garoua, Cameroon Department of Internal Medicine, Garoua Regional Hospital, Garoua, Cameroon
Guy Roussel	Takuissu-Nguemto	tgroussel@yahoo.fr	Laboratory of nutrition and nutritional Biochemistry, Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon
Sophie	Ngo-Boumso	sophia_lesly@yahoo.fr	Department of Hepato-Gastroenrology, CHU de Cocody, University of Felix Houphouet-Boigny, Abidjan, Côte d'Ivoire
Frederic Nico	Njayou	njayou@yahoo.com	Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon
Paul F.	Moundipa	pmoundipa@hotmail.com	Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science University of Yaoundé 1, Yaoundé, Cameroon
Jean Joel	Bigna*	bignarimjj@yahoo.fr	Department of Epidemiology, Centre Pasteur of Cameroon, Yaoundé, Cameroon

4 ***Correspondence to:** Dr. Jean Joel Bigna. Department of Epidemiology and Public Health,
5 Centre Pasteur of Cameroon, Yaoundé, Cameroon. Email: bignarimjj@yahoo.fr

6 **Word count:** 2,578.

7 **Abstract**

8 **Objectives**

9 Although global epidemiology of *Helicobacter pylori* (HP) infection is well characterized,
10 country-specific figure is more accurate for context-specific tailored interventions. The aim
11 was to determine the prevalence, factors associated with infection, antibiotic resistance
12 profile, and genotypes of HP in Cameroon.

13 **Design**

14 A systematic review with meta-analysis.

15 **Participants**

16 People living in Cameroon regardless of their clinical profile.

17 **Data sources and synthesis**

18 Observational studies published in PubMed, EMBASE, African Index Medicus, African
19 Journals Online, and Health Sciences and Diseases up to October 12th, 2020. Study selection,
20 data extraction, and methodological quality assessment were done by two independent
21 authors. Random-effect meta-analysis served to pool prevalence data.

22 **Results**

23 Fifteen studies were included. None investigated the genotypes of HP. Among symptomatic
24 patients, the most common used test, urea breath test on gastric biopsy, yielded a prevalence
25 57.8% (95% confidence interval (CI): 34.3-79.5) of HP infection. This prevalence
26 significantly varied between 47.0% (95%CI: 43.0-51.0) for antigen test in stool samples and
27 71.2% (95%CI: 59.1-81.9) for Giemsa on gastric biopsy; $p = 0.0006$. One study in
28 asymptomatic children reported the prevalence of 52.3% (95%CI: 44.9-59.6) using antigen
29 test for stool samples. Among the six studies investigating factors associated with HP
30 infection, one performed a multivariable model and identified being student as protective

31 factor compared to being employed (Odds ratio: 0.09; 95%CI: 0.02–0.49). For antibiotics
32 used for first line treatment, HP was resistant to amoxicillin (85.6-97.1%), metronidazole
33 (93.2-97.9%), and clarithromycin (13.6-44.7%) as reported in two studies.

34 **Limitation**

35 Data were from six of the ten regions of Cameroon, hindering the generalizability of the
36 findings to the country.

37 **Conclusion**

38 This study depicted a high prevalence of HP infection and a worrying resistance profile to
39 first-line antibiotics. When waiting for well-conducted studies, updated guidelines are needed
40 for clinical practice for first-line antibiotic treatment.

41 **Registration**

42 PROSPERO, CRD42020220084.

43

44 **Keywords**

45 *Helicobacter pylori*; Antimicrobial resistance; Cameroon; Epidemiology

46 **Strengths and limitations of this study**

- 47 • Not all the 10 regions of the country were represented in this study, hindering the
48 generalizability of the findings.
- 49 • We were not able to substantially investigate sources of heterogeneity in the prevalence of
50 *Helicobacter pylori* infection due to scarcity of data.
- 51 • Evidence investigating factors associated with *Helicobacter pylori* infection are weak and
52 there was scarcity on data exploring antibiotic resistance profile of *Helicobacter pylori*.
- 53 • This study is the first to provide an estimate of the epidemiology and resistance profile of
54 *Helicobacter pylori* in Cameroon.

55

56 **Introduction**

57 *Helicobacter pylori* (*H. pylori*) is a Gram negative bacterium belonging in the family of
58 *Helicobacteriaceae*. This bacterium has been isolated from feces, saliva and dental plaques,
59 suggesting that transmission is possible by ingestion of food or water contaminated by the
60 feces through the gastro-oral route or by person-to-person transmission.^{1 2} *H. pylori* infection
61 is global public health concern with 4.4. billion people living with *H. pylori* worldwide.³ The
62 global prevalence of *H. pylori* infection is 44.3%, with the prevalence higher in developing
63 countries (50.8%) and in Africa (70.1%) compared to other regions.³ Although *H. pylori*
64 infection would have a protective effect against esophageal adenocarcinoma and Barrett's
65 esophagus;⁴ *H. pylori* infection increases the risk for gastroesophageal reflux, peptic or
66 duodenal ulcer, and colorectal and gastric cancers.⁵⁻⁹ In addition, *H. pylori* infection is also
67 associated with non-gastrointestinal disorders like diabetes, obesity, acute coronary syndrome,
68 periodontitis, nonalcoholic fatty liver, Sjögren syndrome, systemic sclerosis, pre-eclampsia,
69 and infertility.¹⁰⁻²⁰ Therefore, curbing the burden of these diseases requires targeted
70 interventions to eradicate *H. pylori* infection.^{9 21-23} Antibiotic resistance profile would make
71 difficult the eradication of *H. pylori* infection. Globally, primary and secondary resistance
72 rates to clarithromycin, metronidazole, and levofloxacin were $\geq 15\%$ in all WHO regions,
73 except primary clarithromycin resistance in the Americas (10%) and South-East Asia region
74 (10%) and primary levofloxacin resistance in the European region (11%).²³
75 Although the global and regional epidemiology and antibiotic resistance profile of *H. pylori*
76 infection is characterized, country-specific figure is more accurate for context-specific
77 tailored interventions. To date, there is no systematic review summarizing data on the
78 epidemiology and antibiotic resistance profile of *H. pylori* infection in Cameroon. Therefore,
79 the aim was to determine the prevalence, factors associated with infection, antibiotic
80 resistance profile, and genotypes of *H. pylori* infection in populations living in Cameroon.

81 Such data would help policy makers for national and context-specific interventions, would
82 help for advising local clinical guidelines, and highlight gap between current evidence and
83 new research needed in the country.

84

85 **Methods**

86 **Design**

87 The Joanna Briggs Institute guidelines was used for the methodology of this systematic
88 review and meta-analysis.²⁴ This systematic review and meta-analysis was registered with
89 PROSPERO, number CRD42020220084. This review was reported as per PRISMA
90 guidelines.²⁵

91 **Search strategy**

92 We performed a search of PubMed, Excerpta Medica Database (EMBASE), African Index
93 Medicus, African Journals Online, and the Cameroonian local journal Health Sciences and
94 Diseases to identify relevant studies published on *H. pylori* in Cameroon up to October 12th,
95 2020; regardless of the language of publication. Both text words and medical subject heading
96 terms were used. Search strategy conducted in EMBASE is shown in the Appendix
97 (Supplementary Table 1). A manual search that consists in scanning the reference lists of
98 eligible papers and other relevant review articles was applied.

99 **Eligibility criteria**

100 We considered observational (cross-sectional, case-control, and cohort) studies conducted in
101 general population and populations with specific conditions living in Cameroon. *H. pylori*
102 infection had to be laboratory-diagnosed. Studies had to report the prevalence (or enough data
103 to compute this estimate) or factors associated with *H. pylori* infection, or had to investigate
104 genotypes or the relevant antibiotic (azithromycin, clarithromycin, erythromycin,

105 metronidazole, tetracycline, minocycline, ampicillin, amoxicillin (+ clavulanic acid),
106 levofloxacin, ciprofloxacin, levofloxacin) resistance profile of *H. pylori*.²³ We have not
107 considered studies in which patients self-reported the infection. Studies conducted in
108 Cameroonian living outside Cameroon were not considered.

109 **Study selection**

110 Two review authors independently screened records based on titles and abstracts for
111 eligibility. Full texts of articles deemed potentially eligible were retrieved. Further, these
112 review authors independently assessed the full text of each study for final inclusion.
113 Disagreements when existing were solved through discussion and consensus.

114 **Data extraction and management**

115 Data were extracted using a preconceived data abstraction form. Two review authors
116 independently extracted data including: name of the first author, publication year, study
117 design, setting, sampling method, samples collection period, timing of data collection and
118 analysis, site of recruitment, underlying conditions, number of patients screened, number of
119 patients infected with *H. pylori*, diagnostic techniques used, laboratory samples, genotype
120 profile, antibiotic resistance profile, mean age, factors associated with *H. pylori* infection, and
121 proportion of male participants. Disagreements between review authors were reconciled
122 through consensus.

123 Two review authors assessed the risk of bias in included studies using the tool developed by
124 the Joanna Briggs Institute. Disagreements were solved through discussion and consensus.
125 The following items were considered: sampling method (probabilistic sampling vs. non-
126 probabilistic sampling), diagnostic method of *H. pylori* (direct test [stool antigen test, urea
127 breath test of gastric biopsy samples, culture of gastric biopsy samples, stool culture, PCR] vs.

128 indirect test [antibody detection, saliva, antigen detection]),²⁶ precision (acceptable vs. low),
129 same procedure for diagnostic of *H. pylori* (yes vs. no).

130 **Data synthesis and analysis**

131 Data analyses used the ‘meta’ packages of the statistical software R (version 3.6.3, The R
132 Foundation for statistical computing, Vienna, Austria).²⁷ Single arcsine transformation with
133 random-effects meta-analysis model was used to pool prevalence data of *H. pylori* infection.²⁸
134 Egger’s test served to assess the presence of publication bias.²⁹ A $p < 0.10$ on Egger test was
135 considered indicative of statistically significant publication bias.

136 Heterogeneity was evaluated by the χ^2 test on Cochran’s Q statistic,³⁰ which was quantified I^2
137 values.³¹ The I^2 statistic estimates the percentage of total variation across studies due to true
138 between-study differences rather than chance. In general, I^2 values greater than 60-70%
139 indicate the presence of substantial heterogeneity. We performed a narrative synthesis for
140 antibiotic resistance and factors associated with *H. pylori* infection because of the
141 heterogeneity in reporting these outcomes and scarcity of data.

142

143 **Results**

144 **Study selection and characteristics**

145 We initially identified 77 records and finally retained 15 studies (Figure 1).³²⁻⁴⁶ Agreement
146 between investigators for report selection based on title and abstract was $\kappa = 0.88$, and $\kappa = 1$
147 for final inclusion. Individual characteristics of included studies are in the Supplementary
148 Table 2.

149 Studies were published between 2013 and 2019 and data were collected between 2006 and
150 2018. Fourteen studies were cross-sectional, and one was case control. Fourteen studies were

151 hospital-based, and one was community-based. Data were from six of the ten regions of the
152 country: Centre, Littoral, East, North-West, South-West, and West. Gastric biopsy was done
153 in 10 studies, blood collection in five studies, and stool collection in three studies. Urea
154 breath test were used in eight studies, antibodies were searched in five studies, antigens in
155 three studies, Giemsa in two studies, and PCR in one study. There were fourteen studies
156 reporting prevalence data, four studies that investigated factors associated with *H. pylori*
157 infection, and two that investigated antimicrobial resistance. None of the studies investigated
158 the genotypes of *H. pylori*. One study was conducted among asymptomatic general population
159 of children and the remaining were conducted among symptomatic patients.

160 Two studies performed probabilistic sampling and the remaining non-probabilistic sampling.
161 Twelve studies prospectively analysed data and the remaining retrospectively. The response
162 rate was acceptable in 12 studies and not reported in three studies. (Supplementary Table 2).

163 **Prevalence of *Helicobacter pylori* in Cameroon**

164 Twelve studies investigated the prevalence of *H. pylori* infection. Among symptomatic
165 people,^{32 33 35 37-45} the most common used test, urea breath test on gastric biopsy, yielded a
166 prevalence 57.8% (95%CI: 34.3-79.5), with substantial heterogeneity (Table 1). The
167 prevalence of *H. pylori* infection significantly varied between 47.0% (95%CI: 43.0-51.0) for
168 antigen test in stool samples and 71.2% (95%CI: 59.1-81.9) for Giemsa on gastric biopsy
169 (Figure 1), with significant difference between diagnostic methods, $p = 0.0006$ (Table 1). The
170 publication bias was marginal (Table 1).

171 One study reported the prevalence of *H. pylori* in general population.⁴⁶ The study was
172 conducted among 176 asymptomatic children on stool samples. The prevalence was 52.3%
173 (95%CI: 44.9-59.6) using antigen test.

174 **Factors associated with *Helicobacter pylori* infection in Cameroon**

175 Six studies investigated factors associated with *H. pylori* in symptomatic patients and in
176 general population of children and adults (Table 2).^{32-34 39 40 46} Aminde and colleagues in a
177 retrospective cross-analysis of 451 children and adults with dyspepsia, identified being
178 student (odds ratio [OR]: 0.41; 95%CI: 0.18-0.90) and unemployed/retired (OR: 0.31; 95%CI:
179 0.11-0.87) as protective factor compared to employed, as well as being HIV-infected (OR:
180 0.49; 95%CI: 0.15-0.68).³³ In the multivariable model, only being student remained
181 associated with *H. pylori* immunoglobulins G seropositivity (Table 2).³³

182 The remaining studies did not perform multivariable analysis. Ankouane and colleagues in a
183 9-year retrospective analysis of 115 children and adolescents with peptic ulcer disease did not
184 identify any factor associated with *H. pylori* infection on gastroduodenal biopsies using rapid
185 urease test.³² Ndebi and colleagues in a cross-sectional study of 160 adults consulting in a
186 primary healthcare setting for medical check-up or with hospital admission identified not
187 washing hands after saddles (OR: 10.74; 95%CI: 5.12-22.54), giving of chewed food by the
188 parents to children (OR: 3.38; 95%CI: 1.54-7.40), and borrow water (OR: 0.25; 95%CI: 0.07-
189 0.91).³⁴ Ndip and colleagues in a cross-sectional study of 176 asymptomatic children
190 identified male sex (OR: 2.67; 95%CI: 1.39-5.17), low socioeconomic status (OR: 2.41;
191 95%CI: 1.26-4.64), 2-4 persons in the house (OR: 3.09; 95%CI: 1.53-6.28 versus > 4
192 persons), sucking of thumb/fingers (OR: 6.06; 95%CI: 2.02-19.4), bathing in shared water
193 (OR: 4.10; 95%CI: 1.56-11.2), breastfeeding > 6 months (OR: 0.20; 95%CI: 0.08-0.49; versus
194 < 2 months).^{46 47} Ankouane and colleagues in a cross-sectional study of 171 children and
195 adults identified age > 50 years (RR: 0.73; 95%CI: 0.57-0.93) as factor associated with *H.*
196 *pylori* infection with rapid urease test on gastric biopsies.⁴⁰ Agbor and colleagues in a cross-
197 sectional study of feces from 500 patients consulting for signs and symptoms of chronic
198 gastritis identified age > 50 years (p = 0.021), level of education (prevalence decrease with

199 level of education, $p < 0.001$), source of income (prevalence higher in agriculture, trading,
200 service compared to housewife/retired, $p < 0.001$), source of drinking water (prevalence
201 higher for bottled > spring or tap water; $p = 0.006$), increasing duration of gastric symptom (p
202 = 0.003), toilet system (higher in leads to drainage compared to closed pit; $p = 0.044$), alcohol
203 consumption ($p = 0.027$), smoking status (higher in occasional smokers compared to regular;
204 $p < 0.001$) associated detection of *H. pylori* antigen.³⁹

205 **Antibiotic resistance profile of *Helicobacter pylori* in Cameroon**

206 Two studies reported antibiotic resistance profile of *H. pylori* (Table 3).^{35 36} Ndip and
207 colleagues analysed 132 gastric biopsy specimens for *H. pylori* resistance against four
208 antibiotics (clarithromycin, tetracycline, amoxicillin, and metronidazole). The proportion of
209 resistance varied from 43.9% for tetracycline to 93.2% for metronidazole.³⁵ In a study by
210 Kouitcheu Mabeku and colleagues in 140 gastric biopsy specimens,³⁶ the authors did not find
211 any resistance against azithromycin, ciprofloxacin, and levofloxacin. The resistance was less
212 than 20% for three antibiotics (minocycline, tetracycline, and clarithromycin). The resistance
213 was 47.9% for erythromycin. For the remaining antibiotics, the resistance was higher than
214 95% (amoxicillin, metronidazole, ampicillin (+ clavulanic acid)).

215

216 **Discussion**

217 This systematic review with meta-analysis of 15 studies depicted a high prevalence of *H.*
218 *pylori* infection among different people living in Cameroon using different diagnostic
219 methods. There was a high variability among reported factors associated with this infection.
220 *H. pylori* was resistant to most of antibiotics at 50% level or more.

221 The prevalence of *H. pylori* infection we found in this study is in the range of estimates
222 reported from other countries of Africa (46.8-87.7%) as well as for other regions of the world

223 (44.3%, 95% CI: 40.9-47.7).^{3 48} At the turn of the 21st century, the prevalence of *H. pylori* has
224 been declining in highly industrialized countries of the Western world, whereas prevalence
225 has plateaued at a high level in developing (like in Cameroon) and newly industrialized
226 countries.³ The high prevalence in the country may be explained by poor access to adequate
227 sanitation, poor access to clean water, and low socioeconomic status known to be associated
228 with *H. pylori* infection. The overall situation is concerning in the country. For instance, few
229 (51%) family had access to enough water, a fifth of the communities used exclusively
230 unimproved water sources and 52% mixes both unimproved and improved water sources,
231 31% of the community do not treat drinking water, and only few (67%) people have soap at
232 home and even less have handwashing facilities (63%).⁴⁹ Therefore, curbing the burden of *H.*
233 *pylori* infection required a broad intervention for improving hygiene, sanitation, and water
234 supply profile in the country. Performing systematic and community testing for *H. pylori*
235 could be explored, however, in a resource-limited setting with high burden of other diseases
236 seems to be unrealistic. A focus should be done for patient with high risk of infection; for
237 instance, those with gastroduodenal symptoms.

238 At individual level, several factors have been investigated with *H. pylori* infection; however,
239 only one study performed a multivariable model identifying being student as a protective
240 factor compared to being employed. Multiple factors have been identified in the univariable
241 model, however it is difficult to exploit these findings and make recommendations. Therefore,
242 high-quality and well-conducted community-based epidemiological studies are needed to
243 identify risk factors associated with *H. pylori* infection in the country. Such studies would
244 help to identify country-specific risk factors of *H. pylori* infection and adopt related and
245 tailored recommendations.

246 In Cameroon, first line treatment for *H. pylori* include two main strategies: concomitant
247 quadruple therapy (proton pump inhibitor + amoxicillin + metronidazole + clarithromycin for

248 14 days) and sequential quadruple therapy (proton pump inhibitor + amoxicillin for 5 days,
249 followed by proton pump inhibitor + metronidazole + clarithromycin for 5 days).⁵⁰ As
250 reported in a study conducted among 165 patients, the most used is the first one (63%).⁵⁰
251 From this study, the treatment success rate of these strategies were 73.9% without significant
252 difference between them.⁵⁰ However, using these antibiotics in this context is questionable
253 looking at the findings of the two studies on antibiotic resistance we found. *H. pylori* was
254 resistant to amoxicillin (85.6-97.1%), metronidazole (93.2-97.9%), and clarithromycin (13.6-
255 44.7%). Only clarithromycin had profile resistance < 50%. Therefore, all treatment initiation
256 against *H. pylori* should be guided by the antibiotic resistance profile. However, in a resource-
257 limited setting where the resistance profile test is only (but not all) accessible in
258 secondary/tertiary healthcare facilities, this strategy is unrealistic. Therefore, two strategies
259 should be adopted, one guided by antibiotic resistance profile and the second one based on
260 probabilistic nonresistance profile. The last one requires a broad analysis of *H. pylori*
261 antibiotic resistance profile considering actual evidence and performing a nationally-
262 representative and community-based study to design tailored recommendations for context-
263 specific probabilistic and efficacious first-line antibiotic treatment.

264 The findings of this study should be interpreted with caution. Not all the 10 regions of the
265 country were represented in this study hindering the generalizability of the findings of this
266 study to the entire country. We were not able to substantially investigate sources of
267 heterogeneity in the prevalence of *H. pylori* infection due to scarcity of data, although
268 heterogeneity is practically inevitable in a meta-analysis of prevalence studies. In the absence
269 of a nationally representative population-based study taking into account all regions of the
270 country, this study is the first to provide an estimate of the epidemiology and resistance
271 profile of *H. pylori* in Cameroon without a lot of financial, logistical, and material expenses in
272 the context of a resource-limited country.

273 This study depicted a high prevalence of *H. pylori* infection in both symptomatic and
274 asymptomatic populations. This study also highlights a worrying resistance profile to first-line
275 antibiotics. When waiting for well-conducted studies to identify risk factors associated with
276 *H. pylori* infection and to have a more accurate profile of antibiotic resistance profile, updated
277 guidelines are needed for clinical practice for first-line treatment in the country.

278 **Author contributions:** Conception and design: JJB, MAG, CRN, FNN, FBNS. Search
279 strategy: JJB. Study selection: JJB, FBNS. Data extraction: JJB, CRN, FBNS. Data analysis:
280 JJB and JJN. Manuscript drafting: JJB, CRN, JJN. Manuscript revision: JJB, MAG, PFM,
281 CRN, SNB, FNN, JJN, FBNS, GRTN. Guarantor of the review: JJB. Approved the final
282 version of the manuscript: All authors.

283 **Acknowledgements:** None.

284 **Funding:** This research received no specific grant from any funding agency in the public,
285 commercial or not-for-profit sectors.

286 **Competing interests:** We have read and understood BMJ policy on declaration of interests
287 and declare that we have no competing interests.

288 **Data sharing statement:** All data relevant to the study are included in the article or uploaded
289 as supplementary information.

290

291 **References**

- 292 1. Kayali S, Manfredi M, Gaiani F, et al. Helicobacter pylori, transmission routes and
293 recurrence of infection: state of the art. *Acta bio-medica : Atenei Parmensis*
294 2018;89(8-s):72-76. doi: 10.23750/abm.v89i8-S.7947 [published Online First:
295 2018/12/19]
- 296 2. Mladenova I, Durazzo M. Transmission of Helicobacter pylori. *Minerva*
297 *gastroenterologica e dietologica* 2018;64(3):251-54. doi: 10.23736/s1121-
298 421x.18.02480-7 [published Online First: 2018/02/21]
- 299 3. Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection:
300 Systematic Review and Meta-Analysis. *Gastroenterology* 2017;153(2):420-29. doi:
301 10.1053/j.gastro.2017.04.022 [published Online First: 2017/05/01]
- 302 4. Rokkas T, Pistiolas D, Sechopoulos P, et al. Relationship between Helicobacter pylori
303 infection and esophageal neoplasia: a meta-analysis. *Clinical gastroenterology and*
304 *hepatology : the official clinical practice journal of the American Gastroenterological*
305 *Association* 2007;5(12):1413-7, 17.e1-2. doi: 10.1016/j.cgh.2007.08.010 [published
306 Online First: 2007/11/13]

- 307 5. Mungan Z, Pınarbaşı Şimşek B. Gastroesophageal reflux disease and the relationship with
308 Helicobacter pylori. *The Turkish journal of gastroenterology : the official journal of*
309 *Turkish Society of Gastroenterology* 2017;28(Suppl 1):S61-s67. doi:
310 10.5152/tjg.2017.16 [published Online First: 2017/12/05]
- 311 6. de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in
312 2018: a worldwide incidence analysis. *The Lancet Global health* 2020;8(2):e180-e90.
313 doi: 10.1016/s2214-109x(19)30488-7 [published Online First: 2019/12/22]
- 314 7. Zuo Y, Jing Z, Bie M, et al. Association between Helicobacter pylori infection and the risk
315 of colorectal cancer: A systematic review and meta-analysis. *Medicine (Baltimore)*
316 2020;99(37):e21832. doi: 10.1097/md.00000000000021832 [published Online First:
317 2020/09/15]
- 318 8. Poorolajal J, Moradi L, Mohammadi Y, et al. Risk factors for stomach cancer: a systematic
319 review and meta-analysis. *Epidemiology and health* 2020;42:e2020004. doi:
320 10.4178/epih.e2020004 [published Online First: 2020/02/07]
- 321 9. Ford AC, Gurusamy KS, Delaney B, et al. Eradication therapy for peptic ulcer disease in
322 Helicobacter pylori-positive people. *The Cochrane database of systematic reviews*
323 2016;4(4):Cd003840. doi: 10.1002/14651858.CD003840.pub5 [published Online
324 First: 2016/04/20]
- 325 10. Mansori K, Moradi Y, Naderpour S, et al. Helicobacter pylori infection as a risk factor for
326 diabetes: a meta-analysis of case-control studies. *BMC gastroenterology*
327 2020;20(1):77. doi: 10.1186/s12876-020-01223-0 [published Online First:
328 2020/03/27]
- 329 11. Fang Y, Fan C, Xie H. Effect of Helicobacter pylori infection on the risk of acute
330 coronary syndrome: A systematic review and meta-analysis. *Medicine (Baltimore)*
331 2019;98(50):e18348. doi: 10.1097/md.00000000000018348 [published Online First:
332 2019/12/20]
- 333 12. Wei X, Zhao HQ, Ma C, et al. The association between chronic periodontitis and oral
334 Helicobacter pylori: A meta-analysis. *PLoS One* 2019;14(12):e0225247. doi:
335 10.1371/journal.pone.0225247 [published Online First: 2019/12/12]
- 336 13. Liu R, Liu Q, He Y, et al. Association between Helicobacter pylori infection and
337 nonalcoholic fatty liver: A meta-analysis. *Medicine (Baltimore)* 2019;98(44):e17781.
338 doi: 10.1097/md.00000000000017781 [published Online First: 2019/11/07]
- 339 14. Xu X, Li W, Qin L, et al. Relationship between Helicobacter pylori infection and obesity
340 in Chinese adults: A systematic review with meta-analysis. *PLoS One*
341 2019;14(9):e0221076. doi: 10.1371/journal.pone.0221076 [published Online First:
342 2019/09/12]
- 343 15. Ning L, Liu R, Lou X, et al. Association between Helicobacter pylori infection and
344 nonalcoholic fatty liver disease: a systemic review and meta-analysis. *European*
345 *journal of gastroenterology & hepatology* 2019;31(7):735-42. doi:
346 10.1097/meg.0000000000001398 [published Online First: 2019/04/06]

- 347 16. Chen Q, Zhou X, Tan W, et al. Association between Helicobacter pylori infection and
348 Sjögren syndrome: A meta-analysis. *Medicine (Baltimore)* 2018;97(49):e13528. doi:
349 10.1097/md.00000000000013528 [published Online First: 2018/12/14]
- 350 17. Li X, Peng L, Shen X, et al. The Association between Infertility and Helicobacter pylori
351 Infection: a Meta-Analysis of Case-control Studies. *Clinical laboratory*
352 2018;64(9):1385-93. doi: 10.7754/Clin.Lab.2018.180206 [published Online First:
353 2018/10/03]
- 354 18. Yong WC, Upala S, Sanguankeo A. Helicobacter pylori infection in systemic sclerosis: a
355 systematic review and meta-analysis of observational studies. *Clinical and*
356 *experimental rheumatology* 2018;36 Suppl 113(4):168-74. [published Online First:
357 2018/05/11]
- 358 19. Bellos I, Daskalakis G, Pergialiotis V. Helicobacter pylori infection increases the risk of
359 developing preeclampsia: A meta-analysis of observational studies. *International*
360 *journal of clinical practice* 2018;72(2) doi: 10.1111/ijcp.13064 [published Online
361 First: 2018/02/02]
- 362 20. Nourollahpour Shiadeh M, Riahi SM, Adam I, et al. Helicobacter pylori infection and risk
363 of preeclampsia: a systematic review and meta-analysis. *The journal of maternal-fetal*
364 *& neonatal medicine : the official journal of the European Association of Perinatal*
365 *Medicine, the Federation of Asia and Oceania Perinatal Societies, the International*
366 *Society of Perinatal Obstet* 2019;32(2):324-31. doi: 10.1080/14767058.2017.1378331
367 [published Online First: 2017/09/12]
- 368 21. Du LJ, Chen BR, Kim JJ, et al. Helicobacter pylori eradication therapy for functional
369 dyspepsia: Systematic review and meta-analysis. *World journal of gastroenterology*
370 2016;22(12):3486-95. doi: 10.3748/wjg.v22.i12.3486 [published Online First:
371 2016/03/30]
- 372 22. Lee YC, Chiang TH, Chou CK, et al. Association Between Helicobacter pylori
373 Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis.
374 *Gastroenterology* 2016;150(5):1113-24.e5. doi: 10.1053/j.gastro.2016.01.028
375 [published Online First: 2016/02/03]
- 376 23. Savoldi A, Carrara E, Graham DY, et al. Prevalence of Antibiotic Resistance in
377 Helicobacter pylori: A Systematic Review and Meta-analysis in World Health
378 Organization Regions. *Gastroenterology* 2018;155(5):1372-82.e17. doi:
379 10.1053/j.gastro.2018.07.007 [published Online First: 2018/07/11]
- 380 24. Santos WMD, Secoli SR, Püschel VAA. The Joanna Briggs Institute approach for
381 systematic reviews. *Revista latino-americana de enfermagem* 2018;26:e3074. doi:
382 10.1590/1518-8345.2885.3074 [published Online First: 2018/11/22]
- 383 25. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic
384 reviews and meta-analyses of studies that evaluate healthcare interventions:
385 explanation and elaboration. *BMJ (Clinical research ed)* 2009;339:b2700. doi:
386 10.1136/bmj.b2700 [published Online First: 2009/07/23]

- 387 26. Patel SK, Pratap CB, Jain AK, et al. Diagnosis of *Helicobacter pylori*: what should be the
388 gold standard? *World journal of gastroenterology* 2014;20(36):12847-59. doi:
389 10.3748/wjg.v20.i36.12847 [published Online First: 2014/10/04]
- 390 27. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical
391 tutorial. *Evidence-based mental health* 2019;22(4):153-60. doi: 10.1136/ebmental-
392 2019-300117 [published Online First: 2019/09/30]
- 393 28. Schwarzer G, Chemaitelly H, Abu-Raddad LJ, et al. Seriously misleading results using
394 inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single
395 proportions. *Research synthesis methods* 2019;10(3):476-83. doi: 10.1002/jrsm.1348
396 [published Online First: 2019/04/05]
- 397 29. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
398 graphical test. *BMJ (Clinical research ed)* 1997;315(7109):629-34. doi:
399 10.1136/bmj.315.7109.629 [published Online First: 1997/10/06]
- 400 30. Cochran WG. The Combination of Estimates from Different Experiments. *Biometrics*
401 1954;10(1):101-29. doi: 10.2307/3001666
- 402 31. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses.
403 *BMJ (Clinical research ed)* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557
404 [published Online First: 2003/09/06]
- 405 32. Ankouane F, Ngatcha G, Tagni-Sartre T-S, et al. *Helicobacter Pylori* Infection and Peptic
406 Ulcer Disease in Children and Adolescents from the Age Range of 6 to 18 Years Old
407 in Yaounde (Cameroon). *Health Sciences and Diseases* 2015;16:1-6.
- 408 33. Aminde JA, Dedino GA, Ngwasiri CA, et al. *Helicobacter pylori* infection among patients
409 presenting with dyspepsia at a primary care setting in Cameroon: seroprevalence, five-
410 year trend and predictors. *BMC Infect Dis* 2019;19(1):30. doi: 10.1186/s12879-019-
411 3677-0 [published Online First: 2019/01/10]
- 412 34. Ndebi M, Guimtsop Y, Tamokou JDD. The assessment of risk factors, lipid profile, uric
413 acid and alanine aminotransferase in *Helicobacter pylori*-positive subjects.
414 *International Journal of Research in Medical Sciences* 2018;6:2889-94. doi:
415 10.18203/2320-6012.ijrms20183623
- 416 35. Ndip RN, Malange Takang AE, Ojongokpoko JE, et al. *Helicobacter pylori* isolates
417 recovered from gastric biopsies of patients with gastro-duodenal pathologies in
418 Cameroon: current status of antibiogram. *Tropical medicine & international health :
419 TM & IH* 2008;13(6):848-54. doi: 10.1111/j.1365-3156.2008.02062.x [published
420 Online First: 2008/04/04]
- 421 36. Kouitcheu Mabeku LB, Eyoum Bille B, Tepap Zemnou C, et al. Broad spectrum
422 resistance in *Helicobacter pylori* isolated from gastric biopsies of patients with
423 dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR
424 isolates. *BMC infectious diseases* 2019;19(1):880. doi: 10.1186/s12879-019-4536-8
425 [published Online First: 2019/10/24]

- 426 37. Ankouane F, Ngatcha G, Kowo M, et al. Analyse démographique et endoscopique des
427 patients atteints d'ulcère gastroduodéal à Yaoundé au Cameroun : qu'est ce qui a
428 changé depuis les années 1990 ? *Médecine d'Afrique Noire* 2016
- 429 38. Nell S, Eibach D, Montano V, et al. Recent Acquisition of Helicobacter pylori by Baka
430 Pygmies. *PLoS Genetics* 2013;9(9) doi: 10.1371/journal.pgen.1003775
- 431 39. Agbor NE, Esemu SN, Ndip LM, et al. Helicobacter pylori in patients with gastritis in
432 West Cameroon: prevalence and risk factors for infection. *BMC research notes*
433 2018;11(1):559. doi: 10.1186/s13104-018-3662-5
- 434 40. Andoulo FA, Noah DN, Tagni-Sartre M, et al. [Epidemiology of infection Helicobacter
435 pylori in Yaoundé: specificity of the African enigma]. *The Pan African medical*
436 *journal* 2013;16:115.
- 437 41. Ankouane F, Noah DN, Enyime FN, et al. Helicobacter pylori and precancerous
438 conditions of the stomach: The frequency of infection in a cross-sectional study of 79
439 consecutive patients with chronic antral gastritis in yaoundé, cameroon. *Pan African*
440 *Medical Journal* 2015;20 doi: 10.11604/pamj.2015.20.52.5887
- 441 42. Ebule AI, Longdoh AN, Paloheimo IL. Helicobacter pylori infection and atrophic
442 gastritis. *African Health Sciences* 2013;13(1):112-17.
- 443 43. Eloumou Bagnaka SA, Luma Namme H, Noah Noah D, et al. Risk factors associated with
444 gastroduodenal lesions in a Douala referral hospital (Cameroon). *Medecine et sante*
445 *tropicales* 2016;26(1):104-09. doi: 10.1684/mst.2015.0521
- 446 44. Kouitchou Mabeku LB, Bello Epesse M, Fotsing S, et al. Stool Antigen Testing, a
447 Reliable Noninvasive Method of Assessment of Helicobacter pylori Infection Among
448 Patients with Gastro-duodenal Disorders in Cameroon. *Digestive Diseases and*
449 *Sciences* 2020 doi: 10.1007/s10620-020-06219-0
- 450 45. Ankouane F, Kowo M, Ndjitoyap Ndam AW, et al. The Prevalence of Helicobacter Pylori
451 Infection and Peptic Ulcer Disease in HIV-Positive Patients with Gastrointestinal
452 Symptoms Is not Related to Absolute CD4 Counts: A Case-Control Study. *Health Sci*
453 *Dis* 2016;17(1):1-5.
- 454 46. Ndip RN, Malange AE, Akoachere JFT, et al. Helicobacter pylori antigens in the faeces of
455 asymptomatic children in the Buea and Limbe health districts of Cameroon: A pilot
456 study. *Tropical Medicine and International Health* 2004;9(9):1036-40. doi:
457 10.1111/j.1365-3156.2004.01299.x
- 458 47. Ndip RN, Malange AE, Akoachere JFT, et al. Helicobacter pylori antigens in the faeces of
459 asymptomatic children in the Buea and Limbe health districts of Cameroon: a pilot
460 study. 2004;9(9):1036-40. doi: <https://doi.org/10.1111/j.1365-3156.2004.01299.x>
- 461 48. Zamani M, Ebrahimitabar F, Zamani V, et al. Systematic review with meta-analysis: the
462 worldwide prevalence of Helicobacter pylori infection. *Alimentary pharmacology &*
463 *therapeutics* 2018;47(7):868-76. doi: 10.1111/apt.14561 [published Online First:
464 2018/02/13]

- 465 49. Reach. Water, sanitation, and hygiene needs assessment: Cameroon report: Reach; 2019
466 [Available from:
467 [https://reliefweb.int/sites/reliefweb.int/files/resources/reach_cm_r_report_wash_assess](https://reliefweb.int/sites/reliefweb.int/files/resources/reach_cm_r_report_wash_assessment_december_2018.pdf)
468 [ment_december_2018.pdf](https://reliefweb.int/sites/reliefweb.int/files/resources/reach_cm_r_report_wash_assessment_december_2018.pdf) accessed Jan 09 2020.
- 469 50. Ndjitoyap Ndam AW, Kowo MP, Atangana Messi A, et al. Efficacité de la première ligne
470 de traitement pour l'éradication d'*Helicobacter pylori* dans un pays d'Afrique sub-
471 saharienne. JFHOD: SOCIÉTÉ SAVANTE DES MALADIES ET CANCERS DE
472 L'APPAREIL DIGESTIF, 2020.
- 473

474 **Table 1. Prevalence of *Helicobacter pylori* in patients with gastro-intestinal symptoms or disease* and in children general population**

	Prevalence (95%CI)	N studies	N participants	I ² , %	P heterogeneity	P Egger	P difference
Symptomatic							
• Antigen test	47.0 (43.0-51.0)	2	600	0.0	0.660	NA	0.0006
• PCR, DNA	54.5 (47.2-61.7)	1	178	NA	NA	NA	
• Urea breath test	57.8 (34.3-79.5)	8	1,298	98.5	< 0.0001	0.047	
• Antibody test	62.1 (46.2-76.8)	4	1,190	96.4	< 0.0001	0.074	
• Giemsa	71.2 (59.1-81.9)	1	59	NA	NA	NA	
Asymptomatic children							
• Antigen test	52.3 (44.9-59.6)	1	176	NA	NA	NA	

475 PCR: polymerase chain reaction, DNA: deoxyribonucleic acid, NA: not applicable.

476 * include dyspepsia, gastritis, gastric pain, gastroduodenal ulcer,

477 **Table 2. Factors associated with *Helicobacter pylori* infection in populations living in Cameroon**
 478

Author, year	Population	Diagnostic of <i>H. pylori</i>	Study design	Factors searched	Factors identified in univariable analysis	Factors identified in multivariable analysis
Aminde, 2019 ³³	451 Children and adults (7-96 years) with dyspepsia	Detection of <i>H. pylori</i> IgG antibodies in serum	Retrospective cross-sectional analysis or medical dossiers	Sex, age, marital status, educational level, religion, employment status, HIV status	Employed versus student OR: 0.31; 95%CI: 0.11–0.87; $p = 0.025$; or versus unemployed/retired OR: 0.41; 95%CI: 0.18–0.90; $p = 0.027$	Employed versus student (OR: 0.09 (95%CI: 0.02–0.49; $p = 0.005$))
Ankouane, 2015 ³²	115 Children and adolescents (6-18 years) with peptic ulcer	Rapid urease test of gastro-duodenal biopsies	Retrospective cross-sectional analysis of medical dossiers	Sex, age, localization of ulcer (gastric, duodenal, or both), pain	None identified	Not performed
Ndebi, 2018 ³⁴	160 Adults (31+ years) consulting in primary healthcare setting for medical check-up or admitted in hospital	Detection of <i>H. pylori</i> IgG antibodies in serum	Cross-sectional analysis	Sex, age, marital status, profession, educational level, physical activity, smoking status, alcohol consumption, water source for drinking, washing hands after saddles, eat into same dish, abdominal pain, digestive discomfort, anorexia/thinness, anemia, and giving of chewed food by the parents to children	Not washing hands after saddles (OR: 10.74; 95%CI: 5.12-22.54; $p < 0.001$); giving of chewed food by the parents to children (OR: 3.38; 95%CI: 1.54-7.40; $p = 0.002$); borrow of water (OR: 0.25; 95%CI: 0.07-0.91; $p = 0.025$)	Not performed
Ndip, 2004 ⁴⁷	176 Asymptomatic children	Detection of <i>H. pylori</i> antigens in feces	Cross-sectional analysis	Sex, age, socioeconomic status, number of persons in the house, number of bedrooms in the house, sucking of thumb/fingers, bathing in same water, antibiotic treatment, breastfeeding time	Male sex (OR: 2.67; 95%CI: 1.39-5.17; $p = 0.002$), low socioeconomic status (OR: 2.41; 95%CI: 1.26-4.64; $p = 0.006$), 2-4 persons in the house (OR: 3.09; 95%CI: 1.53-6.28; $p = 0.001$ versus > 4 persons), sucking of thumb/fingers (OR: 6.06; 95%CI: 2.02-19.4; $p = 0.0004$), bathing in same water (OR: 4.10; 95%CI: 1.56-11.2; $p = 0.0023$), breastfeeding > 6	Not performed

					months (OR: 0.20; 95%CI: 0.08-0.49; p = 0.001 versus < 2 months)	
Ankouane, 2013 ⁴⁰	171 children and adults (9-82 years) referred for endoscopy with clinical symptoms and signs gastro-duodenal disease	Rapid urease test of gastro-duodenal biopsies	Cross-sectional analysis	Sex, age, area of habitation, socio-economic status, non-steroid anti-inflammatory drug user	Age > 50 years (RR: 0.73; 95%CI: 0.57-0.93; p = 0.004 versus Age < 40 years)	Not performed
Agbor, 2018 ³⁹	500 consulting for signs and symptoms of chronic gastritis	Detection of <i>H. pylori</i> antigens in feces	Cross-sectional analysis	Sex, age, level of education, source of income, source of drinking water, duration of gastritis symptoms, household population, toileting system, alcohol consumption, smoking status	Age > 50 years (p = 0.021), level of education (prevalence decrease with level of education, p < 0.001), source of income (prevalence higher in agriculture, trading, service compared to housewife/retired, p < 0.001), source of drinking water (prevalence higher for bottled > spring or tapwater; p = 0.006), increasing duration of gastric symptom (p = 0.003), toilet system (higher in leads to drainage compared to closed pit; p = 0.044), alcohol consumption (p = 0.027), higher in occasional smokers compared to regular (p < 0.001)	Not performed

479 *H. pylori*: *Helicobacter pylori*; CI: confidence interval; OR: odds ratio; Ig: immunoglobulins; RR: risk ratio

480 **Table 3. Antibiotic resistance profile of *Helicobacter pylori* in Cameroon**

Author	Sample	Description of antibiotics resistance
Kouitcheu Mabeku, 2019 ³⁶	140 gastric biopsy specimens	Azithromycin 0/140; 0% Ciprofloxacin 0/140; 0% Levofloxacin 0/140; 0% Minocycline 1/140; 0.7% Tetracycline 4/140; 2.9% Clarithromycin 19/140; 13.6% Erythromycin 67/140; 47.9% Amoxicillin 136/140; 97.1% Metronidazole 137/140; 97.9% Ampicillin 140/140; 100% Amoxicillin + clavulanic acid 140/140; 100%
Ndip, 2008 ³⁵	132 gastric biopsy specimens	Tetracycline 58/132; 43.9% Clarithromycin 59/132; 44.7% Amoxicillin 113/132; 85.6% Metronidazole 123/132; 93.2%

481

482

483 **Figures' legend**

484 **Figure 1. Study flow diagram**

485

486 **Figure 2. Prevalence of *Helicobacter pylori* in Cameroon according to different**
487 **diagnostic methods in symptomatic patients**

488 PCR: polymerase chain reaction, DNA: deoxyribonucleic acid



